Current bacteria-mediated cancer therapy clinical trials (14) include Salmonella typhimurium VNP20009 (NCT01099631), an attenuated strain of Salmonella to improve the safety of therapy; SYNB1891 (NCT04167137), a probiotic strain of E. coli Nissle engineered to synthesize Stimulator of Interferon Genes (STING) agonist cyclic di-adenosine monophosphate; and Listeria monocytogenes (NCT02325557), which is commonly used to express and secrete antigen-adjuvant fusion proteins. Here, STING1 is linked to cancer.